OSCR
Oscar Health, Inc.
OSCR's outlook is improving, though it still trails on the overall score.
ZVRA
Zevra Therapeutics, Inc.
ZVRA has the edge over OSCR overall, supported by stronger modeled upside and lower modeled downside.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
ZVRA Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Strong |
ZVRA's revenue, profitability, cash flow and balance sheet are all currently healthy.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over ZVRA in the historical PE scenario, which offers more potential upside but is not a forecast.
ZVRA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 6.4x | $7.75 | -31% |
| Current | 9.2x | $11.16 | — |
| Fair | 11x | $13.47 | +21% |
| Forward | 14x | $11.16 | — |
| Expensive | 24x | $28.69 | +157% |
Historical ranges are pointers, not guarantees.
ZVRA's PE is in its fair range at 9.2x. On analysts' estimates for next year's earnings, today's price would be 14x, in its expensive range.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over ZVRA on the outlook, with more favorable valuation expectations.
ZVRA Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect strong earnings and revenue growth for ZVRA, with profitability improving. However, they disagree widely on these estimates.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
ZVRA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.82 | -32% |
| Q3 2026 | $1.21 | +227% |
| Q2 2026 | $0.94 | +$1.25 |
| Q1 2026 | $2.01 | +$4.01 |
| Q4 2025 | $1.35 | +$3.69 |
| Q3 2025 | $0.37 | +$2.37 |
| Q2 2025 | -$0.31 | +$1.40 |
| Q1 2025 | -$2.00 | -$0.62 |
| Q4 2024 | -$2.34 | -$1.02 |
ZVRA has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR's revenue has grown year over year every quarter since early 2021: $5.1B last quarter, up 72% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
ZVRA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $37.8M | +45% |
| Q2 2026 | $39.7M | +53% |
| Q1 2026 | $36.2M | +78% |
| Q4 2025 | $34.1M | +183% |
| Q3 2025 | $26.1M | +605% |
| Q2 2025 | $25.9M | +482% |
| Q1 2025 | $20.4M | +496% |
| Q4 2024 | $12M | -8.9% |
ZVRA's revenue has grown year over year for seven quarters in a row: $38M last quarter, up 45% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 31% | +15 points |
| Q2 2026 | 42% | +317 points |
| Q1 2026 | 144% | +170 points |
| Q4 2025 | 27% | +155 points |
| Q3 2025 | 16% | +755 points |
| Q2 2025 | -274% | +260 points |
| Q1 2025 | -26% | +572 points |
| Q4 2024 | -128% | -17 points |
ZVRA has the edge over OSCR on profitability, with a higher operating margin.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
ZVRA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $9.8M | +136% |
| Q2 2026 | $16.8M | +$20.6M |
| Q1 2026 | $6.1M | +$14.4M |
| Q4 2025 | $5.5M | +$21.8M |
| Q3 2025 | $4.2M | +$22.3M |
| Q2 2025 | -$3.8M | +$15.3M |
| Q1 2025 | -$8.3M | +$7.8M |
| Q4 2024 | -$16.3M | -$20K |
ZVRA has the edge over OSCR on cash flow, with more consistent year-over-year improvement.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
ZVRA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.6% | +396K shares |
| 1 year | +10% | +5.8M shares |
| 3 years | +78% | +27M shares |
| 5 years | +75% | +26.5M shares |
| Available history | +3231% | +59.9M shares |
ZVRA has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | $3.4M |
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over ZVRA on leverage, with a lower net debt burden relative to earnings.
ZVRA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.3x | Net Cash |
| Q2 2026 | -1.7x | Net Cash |
| Q4 2021 | -14.1x | Net Cash |
| Q3 2021 | -17.3x | Net Cash |
| Q2 2021 | -15.3x | Net Cash |
| Q1 2021 | -14.1x | Net Cash |
ZVRA has more cash than debt.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
ZVRA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 50.9 | Neutral |
| Stochastic | 45.9 | Neutral |
ZVRA's weekly RSI is 51 (neutral) and its Stochastic is 46 (neutral).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
ZVRA PE vs Healthcare Sector
| Metric | ZVRA | Sector median | Relative |
|---|---|---|---|
| PE | 9.2x | 26x | 64% below |
| PE % | 40 | 29 | 11 pts above |
ZVRA has the edge over OSCR on valuation relative to its sector.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over ZVRA on trend strength, trading above more of its moving averages.
ZVRA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $10.7 | 4.8% above |
| 20 week MA | $11.3 | 1.5% below |
| 50 week MA | $10.4 | 7.3% above |
| 100 week MA | $9.66 | 16% above |
| 200 week MA | $7.72 | 45% above |
ZVRA's trend is mixed: it's above four of its five weekly moving averages, and 45% above its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over ZVRA on returns for 2026, with the stronger performance.
ZVRA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $6.69 | $11.5 | +72% |
| 2021 | $11.5 | $8.97 | -22% |
| 2022 | $8.97 | $4.29 | -52% |
| 2023 | $4.29 | $6.55 | +53% |
| 2024 | $6.55 | $8.39 | +28% |
| 2025 | $8.39 | $8.87 | +5.7% |
| 2026 YTD | $8.87 | $11.2 | +26% |
ZVRA has finished higher in four of the last six years, two of them by more than 50%. It's up 26% so far in 2026.